{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-030392","form_type":"8-K","ticker":"SNDX","cik":"0001395937","company_name":"Syndax Pharmaceuticals Inc","filed_at":"2025-03-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:03.513131+00:00","generated_at":"2026-05-25T17:16:47.643028+00:00","sec_items":["2.02","8.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Syndax Q4 Revuforj revenue $7.7M; net loss $94.2M; cash $692.4M","bullets":["Q4 2024 Revuforj net product revenue $7.7M in first five weeks of U.S. launch.","Net loss $94.2M ($1.10/share) for Q4 2024 vs $72.5M ($1.00) in Q4 2023; full year net loss $318.8M ($3.72).","Cash, equivalents and investments $692.4M; expects current resources to fund to profitability.","Launched Niktimvo in Jan 2025 with Incyte; $350M royalty funding from Royalty Pharma on Niktimvo sales.","sNDA for revumenib in R/R mNPM1 AML expected Q2 2025 based on positive AUGMENT-101 data."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-030392","json":"https://secwatch.observer/filing/0000950170-25-030392.json","markdown":"https://secwatch.observer/filing/0000950170-25-030392.md","text":"https://secwatch.observer/filing/0000950170-25-030392.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1395937/000095017025030392/0000950170-25-030392-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1395937/000095017025030392/sndx-20250303.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-25T17:16:47.643028+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}